Lattice Biologics
Lattice Biologics Ltd., a biotech company, develops, manufactures, and markets biologic allograft products for use in the field of cellular therapies and tissue engineering with a focus on bone, skin, and cartilage regeneration worldwide. The last earnings update was 82 days ago. More info.
Add to Portfolio Compare Print
- Lattice Biologics has significant price volatility in the past 3 months.
LBL Share Price and Events
7 Day Returns
1 Year Returns
LBL Shareholder Return
| 7 Day | 30 Day | 90 Day | 1 Year | 3 Year | 5 Year | |
|---|---|---|---|---|---|---|
| Lattice Biologics (LBL) | 0% | 20% | 50% | -57.1% | -85% | - |
| CA Biotechs | 2.8% | 0.7% | 2.1% | -15.5% | -16.7% | 13.6% |
| CA Market | 1% | -2% | 1.9% | -1.6% | 12.9% | 4.6% |
1 Year Return vs Industry and Market
- LBL underperformed the Biotechs industry which returned -15.5% over the past year.
- LBL underperformed the Market in Canada which returned -1.6% over the past year.
Value
Value is all about what a company is worth versus what price it is
available for. If you went into a grocery store and all the bananas were on sale
at half price, they could be considered
undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current
share
price of
Lattice Biologics
to its discounted cash flow analysis.value.The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Below are the data sources, inputs and calculation used to determine the intrinsic value for Lattice Biologics.
| Data Point | Source | Value |
|---|---|---|
| Valuation Model | 2 Stage Free Cash Flow to Equity | |
| Levered Free Cash Flow | Extrapolated from most recent financials. | See below |
| Discount Rate (Cost of Equity) | See below | 13.9% |
| Perpetual Growth Rate | 10-Year CA Government Bond Rate | 1.9% |
An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.
| Data Point | Calculation/ Source | Result |
|---|---|---|
| Risk-Free Rate | 10-Year CA Govt Bond Rate | 1.9% |
| Equity Risk Premium | S&P Global | 6% |
| Biotechs Unlevered Beta | Simply Wall St/ S&P Global | 1.55 |
| Re-levered Beta | = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 1.547 (1 + (1- 21%) (98.35%)) |
2.172 |
| Levered Beta | Levered Beta limited to 0.8 to 2.0 (practical range for a stable firm) |
2 |
| Discount Rate/ Cost of Equity |
= Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 1.95% + (2 * 5.96%) |
13.87% |
Discounted Cash Flow Calculation for TSXV:LBL using 2 Stage Free Cash Flow to Equity Model
The calculations below outline how an intrinsic value for Lattice Biologics is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.
| Levered FCF (USD, Millions) | Source |
Present Value Discounted (@ 13.87%) |
|
|---|---|---|---|
| 2019 | 0.38 | Est @ 92.51% | 0.33 |
| 2020 | 0.63 | Est @ 65.34% | 0.48 |
| 2021 | 0.92 | Est @ 46.32% | 0.62 |
| 2022 | 1.22 | Est @ 33.01% | 0.73 |
| 2023 | 1.51 | Est @ 23.69% | 0.79 |
| 2024 | 1.77 | Est @ 17.17% | 0.81 |
| 2025 | 2.00 | Est @ 12.6% | 0.80 |
| 2026 | 2.18 | Est @ 9.4% | 0.77 |
| 2027 | 2.34 | Est @ 7.17% | 0.73 |
| 2028 | 2.47 | Est @ 5.6% | 0.67 |
| Present value of next 10 years cash flows | $6.75 | ||
| Calculation | Result | |
|---|---|---|
| Terminal Value |
= FCF2028
× (1 + g) ÷ (Discount Rate – g)
= $2.47 × (1 + 1.95%) ÷ (13.87% – 1.95%) |
$21.15 |
| Present Value of Terminal Value |
= Terminal Value ÷ (1 + r)10
= $21.15 ÷ (1 + 13.87%)10 |
$5.77 |
| Calculation | Result | |
|---|---|---|
| Total Equity Value |
= Present value of next 10 years cash flows +
Terminal Value
= $6.75 + $5.77 |
$12.53 |
| Equity Value per Share (USD) |
= Total value / Shares Outstanding
= $12.53 / 93.46 |
$0.13 |
| Calculation | Result | |
|---|---|---|
| Exchange Rate | USD/CAD
(Reporting currency to currency of TSXV:LBL) |
1.342 |
| Value per Share (CAD) |
= Value per Share in USD x Exchange Rate (USD/CAD)
= $0.13 x 1.342 |
CA$0.18 |
| Value per share (CAD) | From above. | CA$0.18 |
| Current discount | Discount to share price of
CA$0.03
= -1 x (CA$0.03 - CA$0.18) / CA$0.18 |
83.3% |
Learn more about our DCF calculations in Simply Wall St’s analysis model .
Current Discount
Current Discount Checks
- Lattice Biologics's share price is below the future cash flow value, and at a moderate discount (> 20%).
- Lattice Biologics's share price is below the future cash flow value, and at a substantial discount (> 40%).
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for
it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing
when they are out of season, or how much your home is worth.The amount the stock market is willing to pay for Lattice Biologics's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are
Lattice Biologics's earnings available for a low price, and how does
this compare to other companies in the same industry?
| Data Point | Source | Value |
|---|---|---|
| Earnings Per Share * | Company Filings (2018-12-31) in USD | $-0.01 |
| TSXV:LBL Share Price ** | TSXV (2019-05-21) in CAD | CA$0.03 |
| TSXV:LBL Share Price converted to USD reporting currency | Exchange rate (CAD/ USD) 0.745 | $0.02 |
| North America Biotechs Industry PE Ratio | Median Figure of 37 Publicly-Listed Biotechs Companies | 19.79x |
| Canada Market PE Ratio | Median Figure of 544 Publicly-Listed Companies | 14.89x |
* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.
** Primary Listing of Lattice Biologics.
| Calculation | Outcome | |
|---|---|---|
| PE Ratio | = TSXV:LBL Share Price ÷ EPS (both in USD) = 0.02 ÷ -0.01 |
-1.72x |
Learn more about our ratios and growth rates in Simply Wall St’s analysis model >
- Lattice Biologics is loss making, we can't compare its value to the North America Biotechs industry average.
- Lattice Biologics is loss making, we can't compare the value of its earnings to the Canada market.
Price based on expected Growth
Does
Lattice Biologics's expected growth come at a high price?
| Data Point | Source | Value |
|---|---|---|
| PE Ratio | See PE Ratio Section | -1.72x |
| Net Income Annual Growth Rate | See Future Growth Section. Line of Best Fit* through Consensus Estimate Earnings of 0 Analysts |
Not available |
| North America Biotechs Industry PEG Ratio | Median Figure of 29 Publicly-Listed Biotechs Companies | 1.12x |
| Canada Market PEG Ratio | Median Figure of 250 Publicly-Listed Companies | 1.14x |
*Line of best fit is calculated by linear regression .
Learn more about our ratios and growth rates in Simply Wall St’s analysis model >
- Unable to calculate PEG ratio for Lattice Biologics, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on
Lattice Biologics's
assets?
| Data Point | Source | Value |
|---|---|---|
| Book Value per Share | Company Filings (2018-12-31) in USD | $-0.06 |
| TSXV:LBL Share Price * | TSXV (2019-05-21) in CAD | CA$0.03 |
| TSXV:LBL Share Price converted to USD reporting currency | Exchange rate (CAD/ USD) 0.745 | $0.02 |
| Canada Biotechs Industry PB Ratio | Median Figure of 36 Publicly-Listed Biotechs Companies | 5.23x |
| Canada Market PB Ratio | Median Figure of 2,405 Publicly-Listed Companies | 1.43x |
| Calculation | Outcome | |
|---|---|---|
| PB Ratio | = TSXV:LBL Share Price ÷ Book Value per Share (both in USD) = 0.02 ÷ -0.06 |
-0.38x |
* Primary Listing of Lattice Biologics.
Learn more about our ratios and growth rates in Simply Wall St’s analysis model >
- Lattice Biologics has negative assets, we can't compare the value of its assets to the CA Biotechs industry average.
Value checks
We assess Lattice Biologics's value by looking at:- Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
- Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
- Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
- Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check) Lattice Biologics has a total score of 2/6, see the detailed checks below.
Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.
Full details on the Value part of the Simply Wall St company analysis model.
Future Performance
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Lattice Biologics has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.
Show me the analysis anyway
The future performance of a company is measured in the same way as past
performance, by looking at estimated
growth
and how much profit it is expected to make.Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Earnings growth vs Low Risk Savings
- Unable to compare Lattice Biologics's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
- Unable to compare Lattice Biologics's earnings growth to the Canada market average as no estimate data is available.
- Unable to compare Lattice Biologics's revenue growth to the Canada market average as no estimate data is available.
Annual Growth Rates Comparison
| Data Point | Source | Value (per year) |
|---|---|---|
| Canada Biotechs Industry Earnings Growth Rate | Market Cap Weighted Average | 28.7% |
| Canada Biotechs Industry Revenue Growth Rate | Market Cap Weighted Average | 37.4% |
| Canada Market Earnings Growth Rate | Market Cap Weighted Average | 14.5% |
| Canada Market Revenue Growth Rate | Market Cap Weighted Average | 6% |
*Line of best fit is calculated by linear regression .
Industry and Market average data is calculated daily.
Learn more about our growth rate calculations in Simply Wall St’s analysis model.
Analysts growth expectations
| Data Point | Source | Value |
|---|---|---|
| Past Financials | Company Filings (4 months ago) | See Below |
| Future Estimates | Average of up to 0 Analyst Estimates (S&P Global) | See Below |
| Date (Data in USD Millions) | Revenue | Cash Flow | Net Income * | Avg. No. Analysts |
|---|
| Date (Data in USD Millions) | Revenue | Cash Flow | Net Income * |
|---|---|---|---|
| 2018-12-31 | 1 | 0 | -1 |
| 2018-09-30 | 1 | 0 | -1 |
| 2018-06-30 | 1 | 0 | -2 |
| 2018-03-31 | 2 | 0 | 0 |
| 2017-12-31 | 2 | 0 | 0 |
| 2017-09-30 | 3 | -1 | -2 |
| 2017-06-30 | 3 | -1 | -2 |
| 2017-03-31 | 3 | -2 | -5 |
| 2016-12-31 | 4 | -2 | -5 |
| 2016-09-30 | 4 | -2 | -8 |
| 2016-06-30 | 4 | -2 | -8 |
| 2016-03-31 | 4 | -2 | -7 |
*GAAP earnings excluding extraordinary items.
Past and Future Earnings per Share
| Data Point | Source | Value |
|---|---|---|
| Past Financials | Company Filings (4 months ago) | See Below |
| Future Estimates | Average of up to 0 Analyst Estimates (S&P Global) | See Below |
All data from Lattice Biologics Company Filings, last reported 4 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.
| Date (Data in USD Millions) | EPS * | EPS High Estimate | EPS Low Estimate | Avg. No. Analysts |
|---|
| Date (Data in USD Millions) | EPS * |
|---|---|
| 2018-12-31 | -0.01 |
| 2018-09-30 | -0.01 |
| 2018-06-30 | -0.02 |
| 2018-03-31 | 0.00 |
| 2017-12-31 | -0.01 |
| 2017-09-30 | -0.02 |
| 2017-06-30 | -0.03 |
| 2017-03-31 | -0.08 |
| 2016-12-31 | -0.09 |
| 2016-09-30 | -0.16 |
| 2016-06-30 | -0.25 |
| 2016-03-31 | -0.16 |
*GAAP earnings excluding extraordinary items.
Performance in 3 years
In the same way as past performance we look at the future estimated return
(profit) compared to the available
funds. We do this looking forward 3 years.
- Unable to establish if Lattice Biologics will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
Future performance checks
We assess Lattice Biologics's future performance by looking at:- Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
- Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Canada market? (1 check)
- Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Canada market? (1 check)
- Is the annual earnings growth rate expected to be above 20%? (1 check)
- Is the annual revenue growth rate expected to be above 20%? (1 check)
- Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Lattice Biologics has a total score of 0/6, see the detailed checks below.
Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.
Full details on the Future part of the Simply Wall St company analysis model.
Past Performance
How has Lattice Biologics performed over the past 5 years?
The past performance of a company can be measured by how much
growth
it has experienced and how much profit it makes relative to the funds and assets
it has available.
Past earnings growth
Past Earnings growth analysis
- Lattice Biologics does not make a profit even though their year on year earnings growth rate was positive over the past 5 years.
- Unable to compare Lattice Biologics's 1-year earnings growth to the 5-year average as it is not currently profitable.
- Unable to compare Lattice Biologics's 1-year growth to the North America Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
All data from Lattice Biologics Company Filings, last reported 4 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.
| Date (Data in USD Millions) | Revenue | Net Income * | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 2018-12-31 | 1.26 | -1.21 | 1.78 | 0.01 |
| 2018-09-30 | 1.16 | -1.23 | 1.87 | 0.00 |
| 2018-06-30 | 1.28 | -1.86 | 1.78 | -0.04 |
| 2018-03-31 | 1.77 | 0.36 | 1.95 | 0.01 |
| 2017-12-31 | 2.21 | -0.44 | 2.61 | 0.08 |
| 2017-09-30 | 2.74 | -1.52 | 3.02 | 0.22 |
| 2017-06-30 | 3.07 | -2.07 | 3.85 | 0.29 |
| 2017-03-31 | 3.36 | -4.91 | 4.06 | 0.25 |
| 2016-12-31 | 3.60 | -5.06 | 3.95 | 0.19 |
| 2016-09-30 | 3.78 | -7.85 | 5.18 | 0.07 |
| 2016-06-30 | 4.08 | -7.59 | 4.65 | 0.05 |
| 2016-03-31 | 4.02 | -7.49 | 4.55 | 0.04 |
| 2015-12-31 | 4.08 | -7.19 | 4.28 | 0.02 |
| 2015-09-30 | 4.19 | -4.06 | 3.01 | |
| 2014-12-31 | 6.11 | -1.50 | 2.20 |
*GAAP earnings excluding extraordinary items.
Performance last year
We want to ensure a company is making the most of what it has available. This is
done by comparing the return (profit) to a company's available
funds,
assets
and
capital.
- It is difficult to establish if Lattice Biologics has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) due to its liabilities exceeding its assets.
- It is difficult to establish if Lattice Biologics has efficiently used its assets last year compared to the North America Biotechs industry average (Return on Assets) as it is loss-making.
- It is difficult to establish if Lattice Biologics improved its use of capital last year versus 3 years ago (Return on Capital Employed) due to its liabilities exceeding its assets.
Past performance checks
We assess Lattice Biologics's performance over the past 5 years by checking for:- Has earnings increased in past 5 years? (1 check)
- Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
- Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
- Is the Return on Equity (ROE) higher than 20%? (1 check)
- Is the Return on Assets (ROA) above industry average? (1 check)
- Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
Lattice Biologics has a total score of 0/6, see the detailed checks below.
Note: We use GAAP Net Income excluding extraordinary items in all our calculations.
Full details on the Past part of the Simply Wall St company analysis model.
Health
How is Lattice Biologics's financial health and their level of debt?
A company's financial position is much like your own financial position,
it includes everything you own
(assets)
and owe
(liabilities).The boxes below represent the relative size of what makes up Lattice Biologics's finances.
The net worth of a company is the difference between its assets and liabilities.
- Lattice Biologics's short term (1 year) commitments are greater than its holdings of cash and other short term assets.
- Lattice Biologics's cash and other short term assets cover its long term commitments.
Balance sheet
Assets
Liabilities and shares
- High level of physical assets or inventory.
- Lattice Biologics has negative shareholder equity (liabilities exceed assets) therefore debt is not covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t
bad,
however if the debt is too high, or the company can’t afford to pay the interest
on its debts this may have impacts in the future.The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.
If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
All data from Lattice Biologics Company Filings, last reported 4 months ago.
| Date (Data in USD Millions) | Total Equity | Total Debt | Cash & Short Term Investments |
|---|---|---|---|
| 2018-12-31 | -5.43 | 2.05 | 0.00 |
| 2018-09-30 | -5.32 | 2.03 | 0.01 |
| 2018-06-30 | -5.10 | 2.53 | 0.00 |
| 2018-03-31 | -4.54 | 2.51 | 0.00 |
| 2017-12-31 | -4.34 | 2.44 | 0.01 |
| 2017-09-30 | -4.26 | 2.41 | 0.02 |
| 2017-06-30 | -3.42 | 2.51 | 0.02 |
| 2017-03-31 | -6.58 | 2.81 | 0.03 |
| 2016-12-31 | -5.97 | 2.91 | 0.00 |
| 2016-09-30 | -5.89 | 2.96 | 0.05 |
| 2016-06-30 | -6.15 | 4.45 | 0.31 |
| 2016-03-31 | -4.97 | 4.32 | 0.52 |
| 2015-12-31 | -4.01 | 3.95 | 0.37 |
| 2015-09-30 | -3.89 | 4.39 | 0.05 |
| 2014-12-31 | -0.11 | 2.84 | 0.27 |
- Lattice Biologics has negative shareholder equity (liabilities exceed assets), this is a more serious situation compared with a high debt level.
- Irrelevant to check if Lattice Biologics's debt level has increased considering it has negative shareholder equity.
CASH RUNWAY ANALYSIS
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
- Whilst loss making Lattice Biologics has sufficient cash runway for more than 3 years if it maintains the current positive free cash flow level.
- Whilst loss making Lattice Biologics has sufficient cash runway for more than 3 years, even with free cash flow being positive and shrinking by -86.9% per year.
Financial health checks
We assess Lattice Biologics's financial health by checking for:- Are short term assets greater than short term liabilities? (1 check)
- Are short term assets greater than long term liabilities? (1 check)
- Has the debt to equity ratio increased in the past 5 years? (1 check)
- Is the debt to equity ratio over 40%? (1 check)
- Is the debt covered by operating cash flow? (1 check)
- Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check) Lattice Biologics has a total score of 3/6, see the detailed checks below.
- Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
- Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
Full details on the Health part of the Simply Wall St company analysis model.
Dividends
What is Lattice Biologics's current dividend yield, its reliability and sustainability?
Dividends are regular cash payments to you from the company, similar to a
bank paying you interest on a savings account.
Annual Dividend Income
If you bought
CA$2,000 of
Lattice Biologics
shares you are expected to receive
CA$0
in your first year as a dividend.
Dividend Amount
- Unable to evaluate Lattice Biologics's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
- Unable to evaluate Lattice Biologics's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not
wildly increasing/decreasing each year. This graph shows you the historical rate
to count toward your assessment of the stock.We also check to see if the dividend has increased in the past 10 years.
| Data Point | Source | Value |
|---|---|---|
| Past Annualized Dividend Yield | S&P Global Market Data | See Below |
| Past Dividends per Share | Company Filings/ Annualized Dividend Payments | See Below |
| Future Dividends per Share Estimates | Average of up to 0 Analyst Estimates (S&P Global) | See Below |
| Global Biotechs Industry Average Dividend Yield | Market Cap Weighted Average of 19 Stocks | 2.4% |
| Canada Market Average Dividend Yield | Market Cap Weighted Average of 331 Stocks | 3.5% |
| Canada Minimum Threshold Dividend Yield | 10th Percentile | 1.2% |
| Canada Bottom 25% Dividend Yield | 25th Percentile | 2% |
| Canada Top 25% Dividend Yield | 75th Percentile | 5.7% |
Industry and Market average data is calculated daily.
Note all dividend per share amounts are annualized and not quarterly or other period.
| Date (Data in $) | Dividend per Share (annual) | Avg. No. Analysts |
|---|
Learn more about our ratios and growth rates in Simply Wall St’s analysis model >
- Unable to perform a dividend volatility check as Lattice Biologics has not reported any payouts.
- Unable to verify if Lattice Biologics's dividend has been increasing as the company has not reported any payouts.
Income/ dividend checks
We assess Lattice Biologics's dividend by checking for:- Firstly is the company paying a notable dividend (greater than 1.2%) - if not then the rest of the checks are ignored.
- Is current dividend yield above the bottom 25% of dividend payers? (1 check)
- Is current dividend yield above the top 25% of dividend payers? (1 check)
- Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
- If they have paid a dividend for 10 years has it increased in this time? (1 check)
- How sustainable is the dividend, can Lattice Biologics afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks) Lattice Biologics has a total score of 0/6, see the detailed checks below.
Full details on the Dividends part of the Simply Wall St company analysis model.
Management
CEO
| COMPENSATION | $381,500 |
| AGE | 53 |
| TENURE AS CEO | 5.4 years |
CEO Bio
Mr. Guy S. Cook has been the Chief Executive Officer of Lattice Biologics Ltd. since December 23, 2013 and also serves as its President. Mr. Cook served as the Chief Executive Officer and Director of Blackstone Ventures Inc. since December 29, 2015. He founded Xtant Medical Holdings, Inc. (formerly Bacterin International Holdings, Inc.) in 1997 served as its Chairman, Chief Executive Officer and President from June 30, 2010 to April 5, 2013. He served as the Chief Scientific Officer of Xtant Medical Holdings, Inc. He served as the Chairman, Chief Executive Officer and President of K-Kitz, Inc. and Bacterin until June 30, 2010. He is considered an international expert in biofilm science and its application. He has more than 25 years of experience organizing, managing and running all aspects of start-up and mid-size businesses. He started his career as a product specialist in the Image Analysis Department of Laboratory Equipment Company in Chicago. Mr. Cook later became President of Delta Resources in Crystal Lake, Illinois, which specialized in developing customized image analysis solutions for the academic community. In 1996, he moved to Montana and worked as a Confocal Microscopist for the Center for Biofilm Engineering at the Montana State University where he developed several proprietary testing models for the medical device industry. He has been Director of Lattice Biologics Ltd since 2015. He served as Director of K-Kitz, Inc. and Bacterin until June 30, 2010. He served as a Director of Xtant Medical Holdings, Inc. from June 30, 2010 to April 5, 2013. He is widely published and was invited to speak at many prominent biofilm conferences, including the Anti-Infective Materials Seminar in Tokyo, Japan and the FDA-CDRH Antimicrobial Device Efficacy Testing Seminar. Mr. Cook attended University of Indiana and received Bachelor of Science degrees in Finance and Economics.
CEO Compensation
- Guy's compensation has increased whilst company is loss making.
- Insufficient data for Guy to establish whether their remuneration is reasonable compared to companies of similar size in Canada.
Management Team
Guy Cook
CEO, President & Director
$382K
53
5.4 yrs
Board of Directors Tenure
Average tenure of the Lattice Biologics board of directors in years:
- The tenure for the Lattice Biologics board of directors is about average.
Board of Directors
Guy Cook
CEO, President & Director
$382K
53
4.3 yrs
Kerry Zang
Chair of the Scientific Advisory Board
1.9 yrs
Donald McInnes
Director
54
25.3 yrs
Kevin Loud
Director
1.9 yrs
Who owns this company?
Recent Insider Transactions
| Announced | Type | Name | Entity | Role | Start | End | Shares | Max Price (CA$) | Value (CA$) | |
|---|---|---|---|---|---|---|---|---|---|---|
| 13. Aug 18 | Buy | Cheryl Farmer | Individual | 10. Aug 18 | 10. Aug 18 | 10,000 | CA$0.05 | CA$517 | ||
| 11. Jul 18 | Buy | Cheryl Farmer | Individual | 10. Jul 18 | 10. Jul 18 | 10,000 | CA$0.07 | CA$721 | ||
| 02. Jul 18 | Buy | Cheryl Farmer | Individual | 29. Jun 18 | 29. Jun 18 | 1,000 | CA$0.07 | CA$74 | ||
| 15. Jun 18 | Buy | Cheryl Farmer | Individual | 15. Jun 18 | 15. Jun 18 | 1,500 | CA$0.11 | CA$167 | ||
| 12. Jun 18 | Buy | Cheryl Farmer | Individual | 11. Jun 18 | 11. Jun 18 | 500 | CA$0.09 | CA$47 | ||
| 07. Jun 18 | Buy | Cheryl Farmer | Individual | 07. Jun 18 | 07. Jun 18 | 10,000 | CA$0.07 | CA$706 | ||
| 05. Jun 18 | Buy | Cheryl Farmer | Individual | 04. Jun 18 | 04. Jun 18 | 10,000 | CA$0.07 | CA$712 | ||
Management checks
We assess Lattice Biologics's management by checking for:- Is the CEO's compensation unreasonable compared to market cap? (1 check)
- Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
- Is the average tenure of the management team less than 2 years? (1 check)
- Is the average tenure of the board of directors team less than 3 years? (1 check) Lattice Biologics has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.
Note: We use the top 6 management executives and board members in our calculations.
Note 2: Insider trading include any internal stakeholders and these transactions .
Full details on the Management part of the Simply Wall St company analysis model.
News
Simply Wall St News
How Does Lattice Biologics Ltd. (CVE:LBL) Affect Your Portfolio Volatility?
Volatility is considered to be a measure of risk in modern finance theory. … Beta is a widely used metric to measure a stock's exposure to market risk (volatility). … Before we go on, it's worth noting that Warren Buffett pointed out in his 2014 letter to shareholders that 'volatility is far from synonymous with risk.' Having said that, beta can still be rather useful.
Simply Wall St - – Full articleWhat Kind Of Investor Owns Most Of Lattice Biologics Ltd (CVE:LBL)?
With a market capitalization of CA$935k, Lattice Biologics is a small cap stock, so it might not be well known by many institutional investors. … Our analysis of the ownership of the company, below, shows that. … Check out our latest analysis for Lattice Biologics
Simply Wall St - – Full articleWho Are Lattice Biologics Ltd's (CVE:LBL) Major Shareholders?
Today, I will be analyzing Lattice Biologics Ltd’s (CVE:LBL) recent ownership structure, an important but not-so-popular subject among individual investors. … The effect of an active institutional investor with a similar ownership as a passive pension-fund can be vastly different on a company's corporate governance and accountability to shareholders. … Therefore, it is beneficial for us to examine LBL's ownership structure in more detail.
Simply Wall St - – Full articleShould You Be Tempted To Buy Lattice Biologics Ltd (CVE:LBL) Because Of Its PE Ratio?
and want to better understand how you can grow your money by investing in Lattice Biologics Ltd (CVE:LBL). … Lattice Biologics Ltd (CVE:LBL) is currently trading at a trailing P/E of 16.1x, which is lower than the industry average of 18.6x. … Although some investors may jump to the conclusion that this is a great buying opportunity, understanding the assumptions behind the P/E ratio might change your mind
Simply Wall St - – Full articleHow Did Lattice Biologics Ltd's (CVE:LBL) Earnings Growth Stack Up Against The Industry?
Below, I will assess Lattice Biologics Ltd's (TSXV:LBL) track record on a high level, to give you some insight into how the company has been performing against its historical trend and its industry peers. … See our latest analysis for Lattice Biologics Did LBL's recent earnings growth beat the long-term trend and the industry? … For Lattice Biologics, its most recent trailing-twelve-month earnings is -US$2.07M, which, relative to the prior year's level, has become less negative.
Simply Wall St - – Full articleIs Lattice Biologics Ltd (TSXV:LBL) An Industry Laggard Or Leader?
Unsuprisingly, this is below the growth rate of the Canadian stock market as a whole. … In the previous year, the industry saw growth in the teens, beating the Canadian market growth of 8.26%. … TSXV:LBL PE PEG Gauge Nov 8th 17 The biotech industry is trading at a PE ratio of 17x, in-line with the Canadian stock market PE of 17x.
Simply Wall St - – Full articleCompany Info
Description
Lattice Biologics Ltd., a biotech company, develops, manufactures, and markets biologic allograft products for use in the field of cellular therapies and tissue engineering with a focus on bone, skin, and cartilage regeneration worldwide. The company offers AmnioBoost, an allograft amniotic fluid visco supplement for the treatment of joint pain associated with osteoarthritis, as well as traditional, spinal, particulate, soft tissue, dental, membrane and barrier, and demineralized bone matrix allografts. Its products are used in a range of applications, including enhancing fusion in spine surgery and breast reconstruction post mastectomy, promotion of bone regeneration in foot and ankle surgery, promotion of skull healing following neurosurgery, enhancing wound repair in burn victims, and subchondral bone defect repair in knee and other joint surgeries, as well as sports medicine indications, such as anterior cruciate ligament repair. The company is headquartered in Belgrade, Montana.
Details
| Name: | Lattice Biologics Ltd. |
| LBL | |
| Exchange: | TSXV |
| Founded: | |
| CA$2,803,749 | |
| 93,458,300 | |
| Website: | http://www.latticebiologics.com |
| Address: |
Lattice Biologics Ltd. 512 East Madison Avenue, Suite 101, Belgrade, Montana, 59714, United States |
Listings
| Exchange Symbol | Ticker Symbol | Security | Exchange | Country | Currency | Listed on | |
|---|---|---|---|---|---|---|---|
| TSXV | LBL | Voting Common Shares | TSX Venture Exchange | CA | CAD | 24. Dec 2015 | |
| OTCPK | LBLT.F | Voting Common Shares | Pink Sheets LLC | US | USD | 24. Dec 2015 | |
| DB | B5G2 | Voting Common Shares | Deutsche Boerse AG | DE | EUR | 24. Dec 2015 |
Number of employees
Current staff
Industry
| Biotechnology | |
| Pharmaceuticals & Biotech |
Company Analysis and Financial Data Status
| Area | Date (UTC time) |
|---|---|
| Company Analysis updated: | 2019/05/22 03:21 |
| End of day share price update: | 2019/05/21 00:00 |
| Last estimates confirmation: | 2019/01/29 |
| Last earnings filing: | 2019/03/01 |
| Last earnings reported: | 2018/12/31 |
| Last annual earnings reported: | 2018/09/30 |
All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
